Welcome to Business Insider‘s daily healthcare newsletter, your daily dose of pharma, biotech, and healthcare news. Subscribe here to get this newsletter in your inbox every weekday.
Today in healthcare news: GoodRx is making its stock-market debut after pricing shares at $33 apiece just after midnight. At that price, the company is valued at $12.7 billion. What a time to be in the digital health/online prescription drug coupon business.
Speaking of vaccines (and when are we not!): Our biotech reporter Andrew Dunn is moderating a conversation on October 5 at 2 p.m. ET on the coronavirus vaccine race with 3 top experts:
- Maria Elena Bottazzi, co-director of Texas Children’s Hospital Center for Vaccine Development
- Art Caplan, bioethicist and founding head of the Division of Medical Ethics at New York University School of Medicine
- Dr. William Haseltine, infectious-disease expert and chair and president of ACCESS Health International
Pharma giant J&J just launched a pivotal 60,000-person coronavirus vaccine trial, and we could learn if the shot works by the end of 2020
- Johnson & Johnson, the world’s largest healthcare company, advanced its coronavirus vaccine candidate into the final stage of clinical trials on Wednesday.
- J&J will recruit up to 60,000 volunteers from around the world, including in the US, South Africa, Brazil, Argentina, Columbia, and Chile, said Paul Stoffels, the pharma giant’s chief scientific officer.
- Dr. Anthony Fauci, the nation’s top infectious-disease expert, estimated that J&J’s trial will likely produce results in December or January.
The coronavirus has killed at least 200,000 people in the United States, another grim milestone for the pandemic
5 experts lay out how they’ll determine whether a coronavirus vaccine is really safe and effective — here’s what to know to evaluate the data for yourself
More stories we’re reading: